2022-502930-25-00CompletedPhase 1/2
Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a therapeutic HPV DC targeting vaccine in patients with Human papillomavirus (HPV)-positive oropharyngeal cancer (HPV.DCVax)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Oct 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 1 Feb 2023
- Start date
- 31 Jul 2023
- Lead sponsor
- Institut Gustave Roussy
- Diseases
- Head and neck cancer
- EU CT number
- 2022-502930-25-00
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 24
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Curie | Paris | France | Completed |
| Institut Gustave Roussy | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.